A vial and a syringe are seen in front of a displayed Moderna logo, in this illustration taken, November 27, 2021. (Photo: REUTERS) |
The vaccine, which was given as a fourth dose in a trial that enrolled more than 800 people, raised virus-neutralizing antibodies by eight-fold against Omicron.
The company said it plans to submit data on the vaccine, which targets Omicron as well as the original coronavirus strain, to regulators in the coming weeks and the doses could be available to consumers in late summer.